Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697996 · ClinicalTrials.gov registry record · Phase 2
Rituximab for Pediatric Renal Transplant Rejection
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00697996: Completed Phase 2 study, sponsored by Stanford University.
NCT00697996 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00697996, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
Interventions
- DRUG Rituximab for transplant rejection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697996
The ClinicalTrials.gov registry entry for NCT00697996 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab for transplant rejection is the first listed.
NCT00697996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00697996 about?
NCT00697996 is a clinical study titled "Rituximab for Pediatric Renal Transplant Rejection". Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
What is the current status of trial NCT00697996?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2005-06. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00697996?
The interventions under investigation include: Rituximab for transplant rejection (DRUG).
Who is sponsoring clinical trial NCT00697996?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.